WESTMINSTER, Colo., Aug. 23, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”) today announced that its Board of Directors (the “Board”) has approved a reverse stock split of ARCA's common stock at a ratio of 1-for-12. ARCA's common stock is expected to begin trading on a post-reverse stock split basis on The Nasdaq Global Market on September 3, 2024, under the new name Oruka Therapeutics, Inc. and under the new symbol “ORKA” following the anticipated closing of the merger with Oruka Therapeutics, Inc. (the “Merger”), with a new CUSIP number 687604108 and ISIN number US6876041087.

Fri, Aug. 23, 2024

Special dividend estimated to be $1.59 per share Payment of special dividend conditioned upon ARCA stockholder approval of the Proposed Merger with Oruka WESTMINSTER, Colo., Aug. 16, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”) today announced that its Board of Directors has declared a special cash dividend (the “Special Dividend”) in connection with the previously announced merger (the “Merger”) with Oruka Therapeutics, Inc. (“Oruka”) pursuant to the Agreement and Plan of Merger and Reorganization, dated April 3, 2024 (the “Merger Agreement”).

Fri, Aug. 16, 2024

WESTMINSTER, Colo., Aug. 01, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), (the “Company”) a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2024 financial results and provided a corporate update.

Thu, Aug. 01, 2024

MILWAUKEE , June 4, 2024 /PRNewswire/ -- Ademi LLP is investigating ARCA (NASDAQ: ABIO) for possible breaches of fiduciary duty and other violations of law in its transaction with Oruka. Click here to learn how to join the https://www.ademilaw.com/case/arca-biopharma-inc or call Guri Ademi toll-free at 866-264-3995.

Tue, Jun. 04, 2024

Cardio Diagnostics (NASDAQ:CDIO – Get Free Report) and ARCA biopharma (NASDAQ:ABIO – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings. Profitability This table compares Cardio Diagnostics and ARCA biopharma’s net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Cardio Diagnostics -34,911.87% -415.33% -216.10% ARCA biopharma N/A -16.08% -15.51% Analyst Ratings This is a summary of current ratings and target prices for Cardio Diagnostics and ARCA biopharma, as reported by MarketBeat. Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardio Diagnostics 0 0 2 0 3.00 ARCA biopharma 0 0 0 0 N/A Cardio Diagnostics presently has a consensus price target of $1.35, indicating a potential upside of 84.93%. Given Cardio Diagnostics’ higher probable upside, equities analysts clearly believe Cardio Diagnostics is more favorable than ARCA biopharma. Volatility & Risk Cardio Diagnostics has a beta of 5.3, meaning that its share price is 430% more volatile than the S&P 500. Comparatively, ARCA biopharma has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Earnings & Valuation This table compares Cardio Diagnostics and ARCA biopharma’s revenue, earnings per share and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardio Diagnostics $20,000.00 828.19 -$8.38 million N/A N/A ARCA biopharma N/A N/A -$5.34 million ($0.42) -7.93 ARCA biopharma has lower revenue, but higher earnings than Cardio Diagnostics. Institutional and Insider Ownership 8.1% of Cardio Diagnostics shares are held by institutional investors. Comparatively, 56.4% of ARCA biopharma shares are held by institutional investors. 30.0% of Cardio Diagnostics shares are held by insiders. Comparatively, 30.9% of ARCA biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Summary ARCA biopharma beats Cardio Diagnostics on 6 of the 10 factors compared between the two stocks. About Cardio Diagnostics (Get Free Report) Cardio Diagnostics Holdings, Inc., an artificial intelligence-powered precision cardiovascular medicine company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. The company was founded in 2017 and is headquartered in Chicago, Illinois. About ARCA biopharma (Get Free Report) ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

Mon, May. 20, 2024